Tag: Menopause / Postmenopause
Menopausal Hormone Therapy Positively Linked to Dementia
Higher hazard ratios noted with increasing duration of use; increased risk seen for those receiving treatment at age 55 years or younger
Common Tools Suboptimal for ID’ing Fracture Risk in Younger Postmenopausal Women
Findings seen for the Fracture Risk Assessment Tool and the Osteoporosis Self-Assessment Tool
Recommendations Updated for Nonhormonal Management of Vasomotor Symptoms
Cognitive behavioral therapy, clinical hypnosis, SSRIs/serotonin-norepinephrine reuptake inhibitors recommended based on level I evidence
Continuous Transdermal Nitroglycerin No Aid for Hot Flashes
No decreases seen in overall frequency or severe hot flash severity at five or 12 weeks
Fracture Risk Up With Prediabetes Before Menopause Transition
Increased risk of fracture after adjustment for confounding variables, including bone mineral density
Catching Extra Sleep on Weekends Tied to Lower Risk for Hyperuricemia
Weekend catch-up of just one to two hours may be enough to provide benefits for postmenopausal women
FDA Approves First Nonhormonal Drug to Ease Menopause Hot Flashes
Veozah targets the neurokinin 3 receptor, which is linked to the regulation of body temperature
Hormone Preparations Tied to Increased Bone Mineral Density in Postmenopausal Women
Findings show a protective effect against osteopenia in both current and past users
Perimenopausal Women Less Likely to Achieve RA Remission
Significantly higher remission seen in association with exogenous sex hormone use for women with rheumatoid arthritis
Women Have Higher Tau, Especially in Setting of Elevated Aβ
Later age at menopause and hormone therapy nonuse also associated with higher regional tau
